A critical phase II study showed that in EGFR-TKI-resistant NSCLC, ICI combined with chemotherapy resulted in good objective remission rates (ORR, 50%) and survival time (PFS, 7.0 months; OS, 23.5 months) (21). This evidence concerns the gene EGFR and non-small cell lung carcinoma.